



VOLUME ONE HUNDRED AND NINE

VITAMINS AND HORMONES

Aldosterone



Series Editor

GERALD LITWACK, PhD

Toluca Lake, North Hollywood, California



ACADEMIC PRESS

An imprint of Elsevier

CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xvii</i>
1. Aldosterone Research: 65 Years, and Counting	1
John W. Funder	
References	13
2. Evolution of the Mineralocorticoid Receptor	17
Michael E. Baker and Yoshinao Katsu	
1. Introduction	18
2. The MR Consists of Multiple Functional Domains	19
3. Evolution of the MR Steroid-Binding Domain	23
4. Aldosterone, the Terrestrial Vertebrate Mineralocorticoid, Is at the End of the Pathway for Corticosteroid Synthesis	23
5. Diverse Steroids Have High Affinity for the MR	26
6. Diverse Steroids Have Different Transcriptional Activity for the MR	27
7. An Evolutionary Puzzle: Progesterone Is a MR Antagonist in Humans and a MR Agonist in Ray-Finned Fish	28
8. Conclusion	30
Acknowledgment	30
Conflict of Interest	30
Funding	31
Author Contributions	31
References	31
3. Mechanisms of Mineralocorticoid Receptor Signaling	37
Peter J. Fuller, Jun Yang, and Morag J. Young	
1. Introduction	38
2. Target Tissues and Ligand Access	40
3. MR Structure and Function	41
4. The Ligand-MR Interaction	43
5. An Interaction Between the NTD and the LBD: The N/C-Interaction	47
6. DNA Binding	48
7. Coregulators for the MR	51

8. Conclusions	58
Acknowledgments	59
Conflict of Interest	59
References	59
Further Reading	68
4. Regulation of Aldosterone Signaling by MicroRNAs	69
Michael B. Butterworth and Diego Alvarez de la Rosa	
1. Introduction to Non-Coding RNAs	70
2. MiR Production	72
3. Regulation of MiR Expression by Aldosterone	74
4. MiR Regulation of Aldosterone Signaling	76
5. Regulation of Related Steroid Hormone Signaling by MiRs	78
6. MiR Role in Modulating Aldosterone Effects in the Kidney	79
7. MiR Regulation of Other Kidney Transporters and Regulatory Proteins	82
8. MiRs in Aldosterone-Related Disease	83
Acknowledgments	93
References	93
5. Aldosterone and Ion Channels	105
William C. Valinsky, Rhian M. Touyz, and Alvin Shrier	
1. Introduction	106
2. Sodium Channels	106
3. Potassium Channels	111
4. Calcium Channels	118
5. Chloride Channels	120
6. Conclusions and Future Directions	121
Acknowledgments	121
References	121
6. Non-Genomic Effects of Aldosterone	133
Anastasia S. Mihailidou, Andreas G. Tzacos, and Anthony W. Ashton	
1. Introduction	134
2. Extra-Nuclear, Non-Genomic Actions Linked to Genomic Actions of Aldosterone	135
3. Role of Second Messenger Pathways	137
4. Controversy of Which Receptor Involved in Non-Genomic Actions of Aldosterone	138
5. Gender Differences in MR Activation: Modeling Sex Hormone-MR Interactions	142
6. Conclusion	145
References	145

7. Mineralocorticoid Receptor Antagonists	151
Anneli Nordqvist and Kenneth L. Granberg	
1. Clinical Use of Mineralocorticoid Receptor Antagonists	152
2. Specific Challenges in Designing Mineralocorticoid Receptor Antagonists	154
3. MR Antagonists That Fit in the Aldosterone Binding Site	156
4. MR Antagonists That Utilize the Met852 Pocket	158
5. The Helix 6–7 Induced Pocket	170
6. Aromatic Sulfonamides as MR Antagonists	171
7. Pyrrole Derivatives as MR Antagonists	172
8. The 1,4-Dihydropyridine Class of MR Antagonists	174
9. The Pyrazoline Class of MR Antagonists	177
10. Oxazolidinone Derivatives as MR Antagonists	179
11. MR Antagonists With a Tricyclic Scaffold	181
12. Summary	182
References	182
8. Adipocyte Mineralocorticoid Receptor	189
Marco Infante, Andrea Armani, Vincenzo Marzolla, Andrea Fabbri, and Massimiliano Caprio	
1. Introduction: The Adipose Organ	190
2. Adipocyte Mineralocorticoid Receptor (MR) and Adipogenesis	194
3. MR and Adipose Tissue Inflammation	195
4. Relationship Between MR Signaling and Browning of WAT	196
5. Novel Concepts Explaining the Obesity-Related Hyperaldosteronism	198
6. Role of Aldosterone/MR System in Metabolic Syndrome	200
7. Therapeutic Perspectives: Use of MR Antagonists in Obesity and Metabolic Syndrome	202
8. Conclusions	203
References	203
9. Inhibitors of Aldosterone Synthase	211
Steven M. Weldon and Nicholas F. Brown	
1. Aldosterone in Health and Disease	212
2. Targeting Aldosterone in Cardiometabolic Disease	212
3. Aldosterone Synthase Inhibitors	215
4. The Next Generation of Aldosterone Synthase Inhibitors	229
5. Summary and Conclusions	232
Acknowledgments	232
References	232

10. Regulation of Aldosterone Secretion	241
Scott M. MacKenzie, Josie C. van Kralingen, and Eleanor Davies	
1. Introduction	242
2. Aldosterone Biosynthesis	243
3. The Renin–Angiotensin System	247
4. Plasma Potassium	251
5. ACTH	251
6. Other Regulators of Aldosterone Secretion	253
7. Common Genetic Polymorphisms Influencing Aldosterone Secretion	255
8. MicroRNAs	257
9. Conclusions	258
Acknowledgments	259
References	259
11. Leptin and Aldosterone	265
Jessica L. Faulkner and Eric J. Belin de Chantemèle	
1. Introduction	266
2. Leptin and Aldosterone in Obesity, a Novel Role to Stimulate Aldosterone	267
3. Implications for the Sex Discrepant Leptin–Aldosterone Relationship in Obesity: Role for Regulation of Blood Pressure in Women	272
4. Conclusion and Perspectives	278
Acknowledgments	279
References	279
12. Primary Aldosteronism: Present and Future	285
John W. Funder	
1. Background	286
2. Primary Aldosteronism: The Present	288
3. Primary Aldosteronism: The Future—Prevalence	292
4. Primary Aldosteronism: The Future—Prognostications	294
Appendix: Primary aldosteronism (PA) for primary care practitioners (PCPs)	298
References	300
13. Paracrine Regulation of Aldosterone Secretion in Physiological and Pathophysiological Conditions	303
Hervé Lefebvre, Céline Duparc, Alexandre Naccache, Antoine-Guy Lopez, Mireille Castanet, and Estelle Louiset	
1. Introduction	304
2. Autocrine/Paracrine Control of Aldosterone Secretion in the Normal Human Adrenal Gland	305

3. Autocrine/Paracrine Mechanisms in Primary Aldosteronism	313
4. Integrated Pathophysiology of Primary Aldosteronism	323
5. Perspectives and Conclusion	327
Acknowledgments	328
References	328
14. Brain Mineralocorticoid Receptors and Resilience to Stress	341
Sofia Kanatsou, Marian Joels, and Harm Krugers	
1. Introduction: Stress and the Hypothalamus Pituitary Adrenal Axis	341
2. Mineralocorticoid Receptor Structure and Expression	343
3. Function of MRs	344
4. Mineralocorticoid Receptors, Gene Variants and Mood	346
5. Effects of MR Overexpression in Relation to Chronic (Early Life) Stress	347
6. The Relevance of Sex Differences	350
7. Discussion and Conclusion	351
References	352
Further Reading	359
15. Aldosterone, the Mineralocorticoid Receptor and Mechanisms of Cardiovascular Disease	361
Morag J. Young and Gail K. Adler	
1. Introduction	362
2. Aldosterone and the Mineralocorticoid Receptor	363
3. Aldosterone and MR Mediated Cardiac Tissue Injury and Dysfunction; the Clinical Perspective	365
4. Preclinical Models for the Elucidation of Aldosterone Regulated Cell-Signaling Pathways of Disease	370
5. MR-Dependent Fibrotic Signaling in the Heart—Mechanisms and Pathways	372
6. The Study of Aldosterone Mediated Cardiac Remodeling Using Transgenic Animal Models	373
Acknowledgments	379
Conflict of Interest Statement	379
References	379
16. Aldosterone and Myocardial Pathology	387
Alessandro Cannavo, Andrea Elia, Daniela Liccardo, Giuseppe Rengo, and Walter J. Koch	
1. Introduction	388
2. Aldo Biosynthesis and Production	389
3. MR: Structure and Function	390

4. Genomic and Non-genomic Signaling Pathways Activated Downstream Aldo/MR System	391
5. Cardiovascular Effects of Aldosterone/MR System: From Cardiac Fibrosis to HF	394
6. Targeting Aldosterone/MR Signaling Pathway as a Novel Strategy to Treat HF Patients	396
7. Conclusions	398
References	400
17. Aldosterone-Producing Adenomas	407
Per Hellman, Peyman Björklund, and Tobias Åkerström	
1. Introduction	408
2. Background	408
3. Epidemiology of PA	409
4. Pathophysiology and Genetic Disturbances	410
5. Low Renin Hypertension/Inappropriate Aldosterone Secretion	420
6. Side-Effects of PA	421
7. Diagnostics	422
8. Treatment	424
9. Outcome	425
10. Summary	426
References	426